<DOC>
	<DOCNO>NCT00002599</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining bone marrow peripheral stem cell transplantation chemotherapy may allow doctor give high dos chemotherapy drug kill cancer cell . Interferon alfa may interfere growth cancer cell . It yet know whether intensive chemotherapy regimen plus stem cell bone marrow transplant effective standard chemotherapy treat patient myeloma . PURPOSE : Randomized phase III trial compare effectiveness two different regimen combination chemotherapy plus interferon alfa without high dose melphalan bone marrow peripheral stem cell transplantation treat patient previously untreated myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Interferon Alfa With Without Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient age 65 myeloma treat standard ABCM ( doxorubicin , carmustine , cyclophosphamide , melphalan ) vs. intensive C-VAMP ( cyclophosphamide , vincristine , doxorubicin , methylprednisolone ) follow high-dose melphalan ( without total-body irradiation ) bone marrow peripheral blood stem cell support , IFN-A maintenance . II . Compare toxicity profile 2 treatment arm . III . Compare 2 treatment arm respect quality life health economics issue . IV . Investigate cellular change mean linked morphology , phenotype , cytogenetics study treatment relapse . OUTLINE : Randomized study . The following acronym use : ABM Autologous Bone Marrow BCNU Carmustine , NSC-409962 CTX Cyclophosphamide , NSC-26271 DOX Doxorubicin , NSC-123127 G-CSF Granulocyte Colony Stimulating Factor ( Amgen ) , NSC-614629 GM-CSF Granulocyte-Macrophage Colony Stimulating Factor ( source specify ) IFN-A Interferon alpha ( Hoffmann-La Roche ) , NSC-367982 L-PAM Melphalan , NSC-8806 MePRDL Methylprednisolone , NSC-19987 PBSC Peripheral Blood Stem Cells PRED Prednisone , NSC-10023 TBI Total-Body Irradiation VCR Vincristine , NSC-67574 ARM I . Induction : 4-Drug Combination Chemotherapy , indicate , 2-Drug Combination Chemotherapy . ABCM : DOX ; BCNU ; CTX ; L-PAM ; , pretreatment ANC platelets less 1,300 75,000 , CTX ; PRED . Maintenance : Biological Response Modifier Therapy . IFN-A . ARM II . Induction : 4-Drug Combination Chemotherapy follow Hematopoietic Stimulation . C-VAMP : DOX ; VCR ; MePRDL ; CTX ; follow CTX ; G-CSF GM-CSF . Consolidation : 3-Drug Combination Chemoablation without Radioablation follow Hematopoietic Rescue . CTX ; L-PAM ; MePRDL ; without TBI use megavoltage equipment ( linear accelerator prefer ) ; follow ABM and/or PBSC . Maintenance : Biological Response Modifier Therapy . IFN-A . PROJECTED ACCRUAL : 750 patient accrue .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Definite myeloma require chemotherapy fulfil least 2 follow criterion : Neoplastic plasma cell infiltrate and/or microplasmacytomas bone marrow aspiration and/or trephine Paraprotein blood and/or urine Definite lytic bone lesion ( simply osteoporosis ) No equivocal myeloma ( patient register Clinical Trial Service Unit , Oxford ) PATIENT CHARACTERISTICS : Age : Under 65 Performance status : Not specify Hematopoietic : ( follow rehydration treatment infection , necessary ) ANC least 1,000 Platelets least 50,000 Hepatic : Not specify Renal : Renal insufficiency necessarily exclude ( dose reduction may applicable ) Cardiovascular : No severe cardiac disease Past history ischemic heart disease may exclude discretion investigator Pulmonary : No severe respiratory illness Other : Ability tolerate least 3 liters/day fluid No lifethreatening disease unrelated myeloma Prior concurrent psychiatric disorder may exclude discretion investigator No prior malignancy except : Nonmelanomatous skin tumor In situ carcinoma PRIOR CONCURRENT THERAPY : No prior therapy minimal local radiotherapy relief bone pain</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>